Ekso Bionics(TM) CEO Nathan Harding to Be Interviewed Live Today on Bloomberg Television's "Taking Stock with Pimm Fox"

RICHMOND, Calif., April 30, 2014 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (OTCQB:EKSO), a robotic exoskeleton pioneer, today announced that CEO Nathan Harding will be interviewed live today by host Pimm Fox on Bloomberg Television's Taking Stock with Pimm Fox. Any interested parties may tune in and listen live via Bloomberg Television's live stream: http://www.bloomberg.com/tv/

The live interview details are as follows:

Date: Wednesday April 30, 2014

Start Time: 5:00pm EDT (U.S.) (estimated scheduled appearance 5:45PM EDT)

Network: Bloomberg Live TV

Show: Taking Stock with Pimm Fox

Host: Pimm Fox

Live television stream: http://www.bloomberg.com/tv/

About Bloomberg Television: is an American-based international cable and satellite business news television channel that is owned by Bloomberg L.P. It is distributed globally, reaching over 310 million homes worldwide. It is primarily headquartered in New York City, with European headquarters in London and Asian headquarters in Hong Kong. http://www.bloomberg.com/tv/

About Pimm Fox: Pimm Fox is a Bloomberg Television anchor and Bloomberg Radio host of the in-depth investment program, "Taking Stock with Pimm Fox", which airs weekdays at 5pm ET. Fox also co-hosts Bloomberg Businessweek Radio with Ken Prewitt on Bloomberg Radio. As the host of "Taking Stock," Fox provides access to the world of professional investors through conversations with top Wall Street analysts, fund managers and CEOs. "Taking Stock" offers insight into company news, long-term strategy, trading tactics, market techniques, stocks, bonds, commodities and currencies. During his career at Bloomberg, Fox has interviewed numerous business chiefs and investment gurus including Berkshire Hathaway Chairman and CEO Warren Buffett.

About Ekso Bionics (OTCQB:EKSO)

Since 2005, Ekso Bionics (http://www.eksobionics.com) has been pioneering the field of robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. The company's first commercially available product called Ekso has helped thousands of people living with paralysis take millions of steps not otherwise possible. By designing and creating some of the most forward-thinking and innovative solutions for people looking to augment human capabilities, Ekso Bionics is helping people rethink current physical limitations and achieve the remarkable.

Facebook: www.facebook.com/eksobionics

Twitter: @eksobionics

YouTube: https://www.youtube.com/user/EksoBionics/

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including, the Company's Current Report on Form 8-K filed on March 31, 2014. The Company does not undertake to update these forward-looking statements.

CONTACT: EKSO Bionics Media Contact:
         Heidi Darling, Marketing Manager
         +1 (415) 302.4777
         hdarling@eksobionics.com

         Investor Contact:
         Lauren Glaser, Vice President
         +1 (646) 378.2972
         lglaser@troutgroup.com

Released April 30, 2014